Logo image of ALMS

ALUMIS INC (ALMS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALMS - US0223071020 - Common Stock

11.43 USD
+0.27 (+2.42%)
Last: 12/9/2025, 8:00:00 PM
11.75 USD
+0.32 (+2.8%)
After Hours: 12/9/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, ALMS scores 3 out of 10 in our fundamental rating. ALMS was compared to 191 industry peers in the Pharmaceuticals industry. While ALMS has a great health rating, there are worries on its profitability. ALMS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALMS has reported negative net income.
ALMS had a negative operating cash flow in the past year.
ALMS Yearly Net Income VS EBIT VS OCF VS FCFALMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -37.24%, ALMS perfoms like the industry average, outperforming 45.03% of the companies in the same industry.
With a Return On Equity value of -46.88%, ALMS perfoms like the industry average, outperforming 53.40% of the companies in the same industry.
Industry RankSector Rank
ROA -37.24%
ROE -46.88%
ROIC N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMS Yearly ROA, ROE, ROICALMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMS Yearly Profit, Operating, Gross MarginsALMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALMS has more shares outstanding
ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALMS Yearly Shares OutstandingALMS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
ALMS Yearly Total Debt VS Total AssetsALMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.47 indicates that ALMS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALMS's Altman-Z score of 2.47 is fine compared to the rest of the industry. ALMS outperforms 62.83% of its industry peers.
ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.47
ROIC/WACCN/A
WACCN/A
ALMS Yearly LT Debt VS Equity VS FCFALMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

ALMS has a Current Ratio of 6.05. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.05, ALMS is doing good in the industry, outperforming 69.11% of the companies in the same industry.
A Quick Ratio of 6.05 indicates that ALMS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.05, ALMS is in the better half of the industry, outperforming 69.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.05
Quick Ratio 6.05
ALMS Yearly Current Assets VS Current LiabilitesALMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

ALMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.89%.
EPS 1Y (TTM)-80.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALMS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.05%
EPS Next 2Y27.89%
EPS Next 3Y19.32%
EPS Next 5Y13.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALMS Yearly Revenue VS EstimatesALMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ALMS Yearly EPS VS EstimatesALMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMS Price Earnings VS Forward Price EarningsALMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMS Per share dataALMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as ALMS's earnings are expected to grow with 19.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.89%
EPS Next 3Y19.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALUMIS INC

NASDAQ:ALMS (12/9/2025, 8:00:00 PM)

After market: 11.75 +0.32 (+2.8%)

11.43

+0.27 (+2.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-17 2026-03-17
Inst Owners47%
Inst Owner Change-0.35%
Ins Owners0.83%
Ins Owner Change41.33%
Market Cap1.19B
Revenue(TTM)20.05M
Net Income(TTM)-227.52M
Analysts87.14
Price Target19.38 (69.55%)
Short Float %5.61%
Short Ratio4.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.82%
Min EPS beat(2)-20.07%
Max EPS beat(2)-19.57%
EPS beat(4)1
Avg EPS beat(4)10.41%
Min EPS beat(4)-20.07%
Max EPS beat(4)83.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-8.3%
EPS NY rev (3m)15.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.71%
Revenue NY rev (3m)10.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 59.5
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 2.75
EV/EBITDA N/A
EPS(TTM)-5.46
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-3.32
FCFYN/A
OCF(TTM)-3.31
OCFYN/A
SpS0.19
BVpS4.65
TBVpS4.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.24%
ROE -46.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.72%
Cap/Sales 8.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.05
Quick Ratio 6.05
Altman-Z 2.47
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)455.91%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.73%
EPS Next Y68.05%
EPS Next 2Y27.89%
EPS Next 3Y19.32%
EPS Next 5Y13.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-90.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.27%
EBIT Next 3Y-4.3%
EBIT Next 5YN/A
FCF growth 1Y-90.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.25%
OCF growth 3YN/A
OCF growth 5YN/A

ALUMIS INC / ALMS FAQ

Can you provide the ChartMill fundamental rating for ALUMIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ALMS.


What is the valuation status of ALUMIS INC (ALMS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALUMIS INC (ALMS). This can be considered as Overvalued.


How profitable is ALUMIS INC (ALMS) stock?

ALUMIS INC (ALMS) has a profitability rating of 1 / 10.


How financially healthy is ALUMIS INC?

The financial health rating of ALUMIS INC (ALMS) is 7 / 10.